tirzepatide shortage fda update declares Mounjaro, Zepbound over Is Compound Tirzepatide Ending? FDA

1 Key results: Semaglutide 2.4 mg: -15.8% body weight loss Liraglutide 3 mg: -6.4% body weight loss Treatment difference: -9.4 percentage points in favour of semaglutide The proportion achieving clinically meaningful weight loss: Important note about Ozempic doses The STEP 8 trial used semaglutide 2.4 mg, which is the Wegovy dose for weight management

Giblin, E

A patient with severe insulin resistance may benefit from staying at 10 mg longer to maximize metabolic improvement, while another person might reach satiety goals at 5 mg and experience diminishing returns at higher doses

& Reisin, E

Once a patient has a prescription for diabetes drug Mounjaro, they can take it to a pharmacy to be filled